Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study
- PMID: 30534039
- PMCID: PMC6257880
Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study
Abstract
Objectives: In Gaza Strip, Palestine, β-thalassemia is a major public health problem where more than 300 β-thalassemia major (βTM) patients are currently being managed at governmental hospitals. We set up to evaluate the hematological and biochemical aspects of our βTM patients at the Gaza European hospital and their correlation with iron overload.
Methods: Our study included 65 transfusion-dependent βTM, as well as 37 apparently healthy subjects as control group. The hematological and biochemical evaluations included complete blood count, coagulation profile liver and kidney function tests, fasting blood sugar, lipid profile, and serum ferritin.
Results: Deteriorated hematological and biochemical statuses were reported in both males and females of βTM patients as compared to the control group. Statistical comparisons showed no significant differences between males and females βTM patients in all parameters except for total cholesterol. The results concerning the splenectomized versus non-splenectomized patients revealed significantly higher values in splenectomized patients for white blood cell (WBC), platelet, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, total protein, cholesterol, and potassium concentration compared to the non-splenectomized patients. Patients infected with hepatitis C virus and/or hepatitis B virus showed significant decrease in WBC count as compared to infection free patients, while for serum urea and creatinine, the virally infected βTM patients revealed significantly higher values compared to infection free patients.
Conclusion: This study justified the necessity for strengthening the efforts for regular evaluation and follow-up of the βTM patients which could be used to improve or modify the management protocols and thus ameliorating their deteriorated hematological and biochemical status.
Keywords: Chelation therapy; iron overload; splenectomy; transfusion; β-thalassemia major.
Similar articles
-
Health Status of Patients With β-Thalassemia in the West Bank: A Retrospective-Cohort Study.Front Med (Lausanne). 2021 Dec 20;8:788758. doi: 10.3389/fmed.2021.788758. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34988098 Free PMC article.
-
Clinical and hematological features among β-thalassemia major patients in Jazan region: A hospital-based study.J Family Med Prim Care. 2020 Jan 28;9(1):412-417. doi: 10.4103/jfmpc.jfmpc_1007_19. eCollection 2020 Jan. J Family Med Prim Care. 2020. PMID: 32110628 Free PMC article.
-
The Relation between Serum Hepcidin, Ferritin, Hepcidin: Ferritin Ratio, Hydroxyurea and Splenectomy in Children with β-Thalassemia.Open Access Maced J Med Sci. 2019 Aug 14;7(15):2434-2439. doi: 10.3889/oamjms.2019.636. eCollection 2019 Aug 15. Open Access Maced J Med Sci. 2019. PMID: 31666842 Free PMC article.
-
Effect of iron overload on renal functions and oxidative stress in beta thalassemia patients.Saudi Med J. 2016 Nov;37(11):1239-1242. doi: 10.15537/smj.2016.11.16242. Saudi Med J. 2016. PMID: 27761563 Free PMC article.
-
Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018064. doi: 10.4084/MJHID.2018.064. eCollection 2018. Mediterr J Hematol Infect Dis. 2018. PMID: 30416696 Free PMC article.
Cited by
-
Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients.Biomedicines. 2022 Jan 17;10(1):189. doi: 10.3390/biomedicines10010189. Biomedicines. 2022. PMID: 35052868 Free PMC article. Review.
-
The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major.J Diabetes Metab Disord. 2020 Jun 3;19(2):767-774. doi: 10.1007/s40200-020-00560-x. eCollection 2020 Dec. J Diabetes Metab Disord. 2020. PMID: 33520802 Free PMC article.
-
Serological and molecular detection of Toxoplasma gondii in ß. thalassemia patients.J Parasit Dis. 2023 Dec;47(4):778-786. doi: 10.1007/s12639-023-01624-4. Epub 2023 Aug 15. J Parasit Dis. 2023. PMID: 38009154 Free PMC article.
-
Health Status of Patients With β-Thalassemia in the West Bank: A Retrospective-Cohort Study.Front Med (Lausanne). 2021 Dec 20;8:788758. doi: 10.3389/fmed.2021.788758. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34988098 Free PMC article.
-
A Compact Differential Dynamic Microscopy-based Device (cDDM): An Approach Tool for Early Detection of Hypercoagulable State in Transfusion-Dependent-β-Thalassemia Patients.ACS Appl Bio Mater. 2024 Jul 15;7(7):4710-4724. doi: 10.1021/acsabm.4c00516. Epub 2024 Jun 26. ACS Appl Bio Mater. 2024. PMID: 38920024 Free PMC article.
References
-
- Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Rev. 2018;32:300–11. - PubMed
-
- Weatherall DJ. The evolving spectrum of the epidemiology of thalassemia. Hematol Oncol Clin North Am. 2018;32:165–75. - PubMed
-
- Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391:155–67. - PubMed
-
- Weatherall DJ. The role of the inherited disorders of hemoglobin, the first “molecular diseases,” in the future of human genetics. Annu Rev Genomics Hum Genet. 2013;14:1–24. - PubMed
-
- Rooks H, Clark B, Best S, Rushton P, Oakley M, Thein OS, et al. A novel 506kb deletion causing epsilongammadeltabeta thalassemia. Blood Cells Mol Dis. 2012;49:121–7. - PubMed
LinkOut - more resources
Full Text Sources